AI Terminal
Fresenius SE & Co. KGaA
Earnings Release • Dec 6, 2018
166_rns_2018-12-06_606c1dbb-9f77-499f-8f0f-8ed9b1121ba0.html
Earnings Release
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 6 December 2018 22:30
Fresenius SE & Co. KGaA: Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019
Fresenius SE & Co. KGaA / Key word(s): Forecast
Fresenius SE & Co. KGaA: Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019
06-Dec-2018 / 22:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019
Current Group expectations for FY 2019
Based on the current status of the Group’s budget process and its FY 2018 guidance, Fresenius expects mid-single digit organic sales growth for FY 2019. Group net income 1,2 , however, is expected to be broadly stable over FY 2018. Fresenius continues to seek both sales growth and efficiency improvement initiatives in order to enhance these expectations.
Current Group expectations
Given its current expectations for FY 2018 and FY 2019, Fresenius now believes its ambitious Group targets for 2020 will not be met.
From 2020 onwards, Fresenius now expects sustainable organic Group sales growth in the mid-single digits. Group net income 2,3 is expected to grow organically slightly faster than sales. Upon Fresenius Kabi’s biosimilars business breaking even, Fresenius expects an acceleration of Group earnings growth. Unlike previous mid-term targets, these expectations exclude the effect of small- to medium-sized acquisitions.
Fresenius will announce detailed FY 2019 financial guidance and mid-term targets with the release of its FY 2018 results on February 20, 2019.
—————————————-
1 In constant currency, before special items and effects of IFRS 16, incl. expenses for the further development of the biosimilars business, H1/18 adjusted for divestitures of Care Coordination activities. 2019 including NxStage operating results.
2 Net income attributable to shareholders of Fresenius SE & Co. KGaA
3 Before special items
—————————————-
For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures .
(Financial statements according to IFRS)
Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
The Management Board
Bad Homburg v.d.H., December 6, 2018
Contact:
Markus Georgi
Senior Vice President Investor Relations
T: +49 (0) 6172 608-2485
End of note
06-Dec-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Fresenius SE & Co. KGaA |
| Else-Kröner-Straße 1 | |
| 61352 Bad Homburg v.d.H. | |
| Germany | |
| Phone: | +49 (0)6172 608-2485 |
| Fax: | +49 (0)6172 608-2488 |
| E-mail: | [email protected] |
| Internet: | www.fresenius.com |
| ISIN: | DE0005785604 |
| WKN: | 578560 |
| Indices: | DAX |
| Listed: | Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange |
| End of Announcement | DGAP News Service |